

NLM Citation: Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006-. Rezafungin. [Updated 2023 May 15]. **Bookshelf URL:** https://www.ncbi.nlm.nih.gov/books/



Rezafungin

Revised: May 15, 2023.

CASRN: 1396640-59-7

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the use of rezafungin during breastfeeding. Because rezafungin is about 90% bound to plasma proteins and has poor oral bioavailability, it is unlikely to reach the milk and be absorbed by the infant. If rezafungin is required by the mother, it is not a reason to discontinue breastfeeding.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Attribution Statement: LactMed is a registered trademark of the U.S. Department of Health and Human Services.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

Alternate Drugs to Consider

Fluconazole, Miconazole

Substance Identification

Substance Name

Rezafungin

CAS Registry Number

1396640-59-7

Drug Class

Breast Feeding

Lactation

Milk, Human

Antifungal Agents

Echinocandins